Food-effect Study of Ecopipam Pharmacokinetics
A Phase 1, Randomized, 2-way Crossover, Food-effect Study of Ecopipam Pharmacokinetics After Administration of the to Be Marketed Tablet in Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Recruitment Department
- Phone Number: 210-225-5437
- Email: Volunteers.SAT@iconplc.com
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78209
- ICON Early Phase Services
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male subjects or female subjects of non-childbearing potential
- ≥18 and ≤55 years of age
- BMI >18.5 and <30.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.
- Subjects must be healthy, as determined by the Investigator, based on medical history, physical examination, ECG, vital signs, and standard panel of blood and laboratory tests at Screening.
- Sexually active males must use a double barrier method of contraception during the study and for at least 90 days after the last dose of study drug.
- Male subjects must be willing not to donate sperm until 90 days following the last study drug administration.
Exclusion Criteria:
- History of significant medical illness
- Clinically significant abnormalities on screening tests/exams
- History of or significant risk of committing suicide
- Donation of plasma within 1 month prior to dosing
- Donation or significant loss of blood within 8 weeks prior to the first dosing
- Major surgery within 3 months or minor surgery within 1 month prior to admission
- Use of prohibited prescription, over-the-counter medications or natural health products
- Use of tobacco or nicotine products within 1 month prior to Screening
- Significant alcohol consumption or history of abuse
- History of drug abuse within the previous 2 years, or a positive drug screen
- History of cannabinoid use within the previous 3 months
- Positive urine drug screen, urine cotinine test, or alcohol breath test
- History of allergy to study medications
- Recent participation in a clinical research study
- Prior exposure to ecopipam
- Not suitable for study in the opinion of the Principal Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Dosed in fasted state
Ecopipam will be taken in the morning in a fasted state
|
A single ecopipam 89.6 mg tablet (equivalent to ecopipam HCl 100 mg)
|
|
Other: Dosed in fed state
Ecopipam will be taken in the morning after a standard high-fat breakfast
|
A single ecopipam 89.6 mg tablet (equivalent to ecopipam HCl 100 mg)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax of ecopipam after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Tmax of ecopipam after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUC of ecopipam after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUCinf of ecopipam after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUClast of ecopipam after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Cmax of ecopipam after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Tmax of ecopipam after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUC of ecopipam after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUClast of ecopipam after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUCinf of ecopipam after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax of EBS-101-40853 after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Tmax of EBS-101-40853 after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUClast of EBS-101-40853 after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUCinf of EBS-101-40853 after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Cmax of EBS-101-40853 after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Tmax of EBS-101-40853 after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUClast of EBS-101-40853 after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUCinf of EBS-101-40853 after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Cmax of ecopipam glucuronide after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Tmax of ecopipam glucuronide after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUClast of ecopipam glucuronide after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUCinf of ecopipam glucuronide after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Cmax of ecopipam glucuronide after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Tmax of ecopipam glucuronide after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUClast of EBS-101-40853 glucuronide after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUCinf of EBS-101-40853 glucuronide after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Cmax of EBS-101-40853 glucuronide after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Tmax of EBS-101-40853 glucuronide after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUClast of EBS-101-40853 glucuronide after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUCinf of EBS-101-40853 glucuronide after administration of an ecopipam tablet in the fed state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Cmax of EBS-101-40853 glucuronide after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Tmax of EBS-101-40853 glucuronide after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUClast of ecopipam glucuronide after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
AUCinf of ecopipam glucuronide after administration of an ecopipam tablet in the fasted state
Time Frame: Up to Day 13
|
Up to 36 samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 13
|
|
Safety and tolerability as demonstrated by concomitant medications
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Safety and tolerability as demonstrated by physical exams
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Safety and tolerability as demonstrated by AEs
Time Frame: Up to Day 20
|
Subjects will be continually monitored for adverse events
|
Up to Day 20
|
|
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) (mmHG)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Respiratory rate (breaths/minute)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Oral temperature (degrees Celsius)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Electrocardiogram (ECG) parameters: HR, PR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) (Milliseconds)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Values of white blood cell (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelets (1000/mm3)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Value of hematocrit (percent)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Value of hemoglobin (g/dL)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Red blood cell (RBC) count (M/mm3)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Values of bicarbonate, sodium, magnesium, potassium, chloride (mmol/L)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Values of urea, phosphorus, calcium, glucose, total cholesterol, HDL, LDL, triglycerides, uric acid, and total, direct and indirect bilirubin (mg/dL)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Values of albumin and total protein (g/dL)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Values of amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST),alkaline phosphatase (ALP), creatine phosphokinase (CPK), and creatinine (U/L)
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Value of urine pH
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Value of urine glucose
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Value of urine protein
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Value of urine blood
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
|
Value of urine leukocyte esterase by dipstick
Time Frame: Up to Day 20
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 20
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Frederick Munschauer, MSc, MD, FAAN, Emalex Biosciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EBS-101-HV-107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.